Keymed Biosciences Inc.: Keymed Biosciences Announces Approval of Stapokibart For the ...
Keymed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental ...
Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic ...
KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of ...
emjreviews.com17 小时
NICE Endorses First-of-Its-Kind Allergic Rhinitis Treatment
Discover how a newly recommended immunotherapy works by gradually increasing the body’s resistance to house dust mites.